...
首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism.
【24h】

Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism.

机译:丙酸氟替卡松通过IL-10依赖性机制增加了变应原刺激的CD4CD25 T细胞对CD4CD25 T调节细胞的抑制作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Corticosteroids are the most effective anti-inflammatory therapy for allergic diseases, and these drugs inhibit T(H)2 T-cell activation. We previously reported that CD4(+)CD25(+) T cells from atopic donors suppressed allergen-stimulated T cells less than those from nonatopic donors. OBJECTIVE: We sought to determine the effect of fluticasone propionate (FP) on allergen-stimulated CD4(+)CD25(-) T cells and on the suppressive ability of CD4(+)CD25(+) T cells. METHODS: CD4(+)CD25(+) and CD4(+)CD25(-) T cells were separated from peripheral blood of atopic and nonatopic volunteers and cultured alone or mixed in the presence of allergen. Effects of FP were assessed by means of addition to cultures or preincubation with CD4(+)CD25(+) T cells. RESULTS: FP inhibited allergen-stimulated proliferation of CD4(+)CD25(-) T cells in a dose-dependent manner. Preincubation of CD4(+)CD25(+) T cells in FP increased subsequent suppressive activity of these cells in allergen-stimulated cultures with CD4(+)CD25(-) T cells. This effect was seen when cells were obtained from both nonatopic and atopic donors but was less for cells obtained from atopic individuals. Prior exposure of CD4(+)CD25(+) T cells to FP also increased subsequent IL-10 production by these cells when stimulated with allergen, and addition of anti-IL-10 antibody reversed the steroid-induced enhancement of suppression in mixed cultures. CONCLUSION: Increased suppression by CD4(+)CD25(+) T cells might play a role in anti-inflammatory effects of corticosteroids in asthma and allergic diseases.
机译:背景:皮质类固醇是过敏性疾病最有效的抗炎疗法,这些药物抑制T(H)2 T细胞活化。我们以前报道过,特应性供体的CD4(+)CD25(+)T细胞抑制的过敏原刺激性T细胞比非特应性供体的抑制性要少。目的:我们试图确定丙酸氟替卡松(FP)对过敏原刺激的CD4(+)CD25(-)T细胞和对CD4(+)CD25(+)T细胞的抑制能力。方法:从特应性和非特应性志愿者的外周血中分离CD4(+)CD25(+)和CD4(+)CD25(-)T细胞,并单独或在变应原存在下混合培养。通过添加到培养物中或与CD4(+)CD25(+)T细胞预孵育来评估FP的作用。结果:FP剂量依赖性抑制变应原刺激的CD4(+)CD25(-)T细胞增殖。 FP中CD4(+)CD25(+)T细胞的预孵育增加了这些细胞在带有CD4(+)CD25(-)T细胞的变应原刺激培养物中的抑制活性。当从非特应性和特应性供体两者中获得细胞时,可以看到这种效果,但对特应性个体的细胞却没有效果。当用变应原刺激时,先前将CD4(+)CD25(+)T细胞暴露于FP也增加了这些细胞的后续IL-10产生,并且添加抗IL-10抗体逆转了类固醇诱导的混合培养抑制作用的增强。结论:CD4(+)CD25(+)T细胞抑制作用的增强可能在皮质类固醇对哮喘和过敏性疾病的抗炎作用中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号